| Patient | Ann Richards |
|---|---|
| Date of birth | 1962-09-01 |
| Identifiers | MRN HR-ML019-SYN; SSN (made up) 000-19-3381 |
| Document date | 2026-05-12 |
| Author | Rosalind Teague, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month bone health review before the first zoledronic acid infusion. [S]
Ms. Richards returns three months after intake. She has taken vitamin D3 2000 units every day and keeps her calcium at about 1200 mg a day from food. She collected the 24-hour urine sample over the weekend, and the result came back this morning with her blood tests. Her routine dental examination three weeks ago found no problems and no dental work is planned. She finished all 16 sessions of the balance and strength program four days ago and now does the home program three times a week. She has had no falls. She has had no alcohol. She has read about the infusion and asked about the flu-like reaction that can follow a first dose. [S]
| Element | Detail |
|---|---|
| Vitamin D | D3 2000 units daily, no missed doses |
| Dental status | Routine examination three weeks ago; no work planned |
| Balance program | 16 of 16 sessions; home program three times a week |
| Falls | None |
| Recovery | No alcohol; no cravings |
| System | Result | Finding |
|---|---|---|
| Musculoskeletal | Negative | No bone, back, or thigh pain |
| Genitourinary | Negative | No kidney stones or urinary symptoms |
| Constitutional | Negative | No fever or recent illness; drinking plenty of fluid today |
| Psychiatric | Negative | Mood good; no cravings; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral tablet, one tablet daily | One tablet by mouth daily | Oral route | 2026-02-10 | active | S |
| Zoledronic acid 5 mg in 100 mL intravenous infusion over 30 minutes, once every 12 months | Once every 12 months, given in the clinic infusion room after a calcium and creatinine check | Intravenous route | 2026-05-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets every 6 hours as needed for aches or fever for up to three days after the infusion (no more than 3 g a day) | Two tablets every 6 hours as needed for up to three days after the infusion | Oral route | 2026-05-12 to 2026-05-15 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-12 | Body height | 164 | cm | S |
| 2026-05-12 | Body weight | 66.4 | kg | S |
| 2026-05-12 | Body mass index (BMI) [Ratio] | 24.7 | kg/m2 | S |
| 2026-05-12 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-05-12 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-05-12 | Heart rate | 72 | /min | S |
| 2026-05-12 | Respiratory rate | 14 | /min | S |
| 2026-05-12 | Body temperature | 36.6 | Cel | S |
| 2026-05-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-12 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 38 | ng/mL | Target 30 ng/mL or higher before and during osteoporosis treatment | Normal | S |
| 2026-05-12 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-05-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1 mg/dL | Normal | S |
| 2026-05-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 81 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-12 | Calcium [Mass/time] in 24 hour Urine | 172 | mg/(24.h) | 100-300 mg/(24.h) | Normal | S |
Vital signs recorded on 2026-05-12; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 66.4 kg |
| Mouth | Good dentition; no exposed bone |
| Gait and balance | Timed Up and Go 9 seconds; tandem stance 18 seconds |
| Spine | No tenderness or kyphosis |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Low bone mass (osteopenia) of the lumbar spine and hip on DXA, lowest T-score -2.3 at the lumbar spine (femoral neck -2.0, total hip -1.7), with a 10-year FRAX risk above the treatment thresholds (major osteoporotic fracture 22 percent, hip 3.6 percent); not osteoporosis by T-score, but meets the AACE 2020 clinical criteria for osteoporosis (low bone mass with a FRAX risk above threshold) | active | confirmed | M85.89 | S — Synthetic modern DXA and FRAX classification linked to her publicly described osteopenia (early osteoporosis) after a fall with a hand fracture. |
| Alcohol use disorder in sustained remission for more than fifteen years, since treatment; no alcohol since | active | confirmed | F10.21 | S — Synthetic modern coding of her publicly described heavy drinking and long recovery; listed because remission protects bone and lowers fall risk, and it is reviewed at each visit. |
| History of falls: a fall from standing height with a hand fracture last year (and, in one account, a second fall with an ankle fracture); no falls since | active | confirmed | Z91.81 | S — Synthetic modern entry linked to her publicly described falls and fractures. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | 25-hydroxyvitamin D | At baseline; after repletion until 30 ng/mL or more; then yearly | Completed today | 38 ng/mL, up from 24; at target; next yearly |
| Laboratory | Serum calcium before each intravenous antiresorptive dose | Before each zoledronic acid dose | Completed today | 9.5 mg/dL, normal; infusion given |
| Laboratory | Creatinine and eGFR before each zoledronic acid dose | Before each dose; do not give if creatinine clearance is below 35 mL/min | Completed today | Creatinine 0.8 mg/dL, eGFR 81 |
| Laboratory | 24-hour urine calcium | At diagnosis, before starting therapy | Completed today | 172 mg in 24 hours, normal; no hypercalciuria. Deviation: collected about three months after it was ordered, because the sample was missed before the four-week visit. No harm resulted: no drug was started until it was done, and the result is normal. Corrective action: baseline tests that need a home collection are now scheduled with the patient before she leaves the intake visit |
| Laboratory | Bone-turnover marker (fasting serum CTX) | Baseline, then 3 to 6 months after starting or changing therapy | Due | Baseline 560 pg/mL; repeat at the six-month visit, three months after today's dose |
| Medication safety | Dental examination before an antiresorptive | Before starting a bisphosphonate or denosumab | Completed today | Routine examination three weeks ago with no problems; no invasive dental work planned |
| Medication safety | First zoledronic acid dose | Yearly | Completed today | 5 mg intravenously over 30 minutes; acetaminophen plan given for the acute-phase reaction |
| Imaging | Central DXA of the spine and hip | Every 1 to 2 years on therapy until stable, on the same scanner | Up to date | Repeat two years after starting therapy |
| Examination | Standing height by stadiometer | Yearly; vertebral imaging again if height falls 2 cm or more | Up to date | 164.0 cm at intake; unchanged on today's vital signs |
| Examination | Fall-risk screen | Yearly, and with any fall | Completed today | After the balance program: Timed Up and Go 9 seconds, tandem stance 18 seconds; no falls |
| Survey | Calcium intake assessment | At baseline and yearly | Up to date | About 1200 mg a day from food |
| Medication safety | Drug-holiday eligibility | After 3 yearly zoledronic acid doses or 5 years of an oral bisphosphonate | Not indicated | First dose today; reassess after the third yearly dose |
| Self-management | Balance and strength exercise program | With a history of falls or impaired balance | Completed today | 16 of 16 sessions finished four days ago; home program three times a week |
| Self-management | Recovery check (alcohol, cravings, stress) | Every visit | Completed today | No alcohol; no cravings |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in her phone |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); The clinician's guide to prevention and treatment of osteoporosis (2022); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020); Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019); STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Zoledronic acid infusion today. Call the clinic for fever lasting more than three days, muscle cramps or tingling, or jaw pain. Six-month bone health review in three months with fasting CTX and calcium. Next scheduled visit 2026-08-11: six-month bone health review, three months after the first infusion. [S]